Ewha Med J.  2024 Jul;47(3):e35. 10.12771/emj.2024.e35.

Influenza disease burden and the need for highly immunogenic vaccines in older adults: a narrative review

• Song JY

• KMID: 2558572
• DOI: http://doi.org/10.12771/emj.2024.e35

Abstract

Influenza presents a considerable disease burden, particularly among adults over 65 years old. In this population, the disease is associated with high rates of infection, hospitalization, and mortality. The objective of this study was to assess the impact of influenza on older adults and to evaluate the effectiveness of influenza vaccines within this demographic. A literature search was conducted using PubMed to identify relevant English-language studies published from January 2000 to January 2024. The analysis indicated that influenza-related hospitalization rates (ranging from 10.1 to 308.3 per 100,000 persons) and all-cause excess mortality rates (1.1 to 228.2 per 100,000 persons) were notably high in older adults, although these rates varied over time and by location. Hospitalization rates due to influenza increased considerably after the age of 50 years, with the highest rates observed in individuals aged 85 years and older. Excess mortality attributable to influenza also rose with age, with rates between 17.9 and 223.5 per 100,000 persons in those over 75 years old. The effectiveness of influenza vaccines in preventing severe infections requiring hospitalization was found to be only 37% in individuals aged 65 years and older. The unadjuvanted, standard-dose influenza vaccine had an estimated effectiveness of just 25% against laboratory-confirmed influenza and between 37% and 43.7% in preventing hospitalizations. Therefore, considering the substantial burden of influenza and the limited efficacy of standard vaccines, the use of highly immunogenic influenza vaccines should be prioritized for older adults.

Keyword

Aged; Hospitalization; Influenza vaccines; Morbidity; Vaccine efficacy

Reference

References

1. Yang TU, Song JY, Noh JY, Cheong HJ, Kim WJ. Influenza and pneumococcal vaccine coverage rates among patients admitted to a teaching hospital in South Korea. Infect Chemother. 2015; 47(1):41–48. DOI: 10.3947/ic.2015.47.1.41. PMID: 25844262. PMCID: PMC4384449.

2. Cassini A, Colzani E, Pini A, Mangen MJJ, Plass D, McDonald SA, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Eur Surveill. 2018; 23(16):17–00454. DOI: 10.2807/1560-7917.ES.2018.23.16.17-00454. PMID: 29692315. PMCID: PMC5915974.

3. Kang SH, Cheong HJ, Song JY, Noh JY, Jeon JH, Choi MJ, et al. Analysis of risk factors for severe acute respiratory infection and pneumonia and among adult patients with acute respiratory illness during 2011-2014 influenza seasons in Korea. Infect Chemother. 2016; 48(4):294–301. DOI: 10.3947/ic.2016.48.4.294. PMID: 27883375. PMCID: PMC5204008.

4. Fischer WA 2nd, Gong M, Bhagwanjee S, Sevransky J. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart. 2014; 9(3):325–336. DOI: 10.1016/j.gheart.2014.08.004. PMID: 25667184. PMCID: PMC4327778.

5. Chun BC. Epidemiology and surveillance of influenza. In. Kim WJ, editor. editor. Influenza. Seoul: Transgovernmental Enterprise for Pandemic Influenza in Korea (TEPIK);2016.

6. Ortiz JR, Neuzil KM, Rue TC, Zhou H, Shay DK, Cheng PY, et al. Population-based incidence estimates of influenza-associated respiratory failure hospitalizations, 2003 to 2009. Am J Respir Crit Care Med. 2013; 188(6):710–715. DOI: 10.1164/rccm.201212-2341OC. PMID: 23855650.

7. Chan PKS, Tam WWS, Lee TC, Hon KL, Lee N, Chan MCW, et al. Hospitalization incidence, mortality, and seasonality of common respiratory viruses over a period of 15 years in a developed subtropical city. Medicine. 2015; 94(46):e2024. DOI: 10.1097/MD.0000000000002024. PMID: 26579810. PMCID: PMC4652819.

8. Lemaitre M, Fouad F, Carrat F, Crépey P, Gaillat J, Gavazzi G, et al. Estimating the burden of influenza-related and associated hospitalizations and deaths in France: an eight-season data study, 2010–2018. Influenza Other Respir Viruses. 2022; 16(4):717–725. DOI: 10.1111/irv.12962. PMID: 35014194. PMCID: PMC9178052.

9. Hong TH, Lee HS, Kim NE, Lee KJ, Kim YK, An JN, et al. Recent increases in influenza-related hospitalizations, critical care resource use, and in-hospital mortality: a 10-year population-based study in South Korea. J Clin Med. 2022; 11(16):4911. DOI: 10.3390/jcm11164911. PMID: 36013150. PMCID: PMC9410240.

10. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018; 391(10127):1285–1300. DOI: 10.1016/S0140-6736(17)33293-2. PMID: 29248255.

11. Schmidt SSS, Iuliano AD, Vestergaard LS, Mazagatos-Ateca C, Larrauri A, Brauner JM, et al. All-cause versus cause-specific excess deaths for estimating influenza-associated mortality in Denmark, Spain, and the United States. Influenza Other Respir Viruses. 2022; 16(4):707–716. DOI: 10.1111/irv.12966. PMID: 35194940. PMCID: PMC9178070.

12. Nielsen J, Mazick A, Glismann S, Mølbak K. Excess mortality related to seasonal influenza and extreme temperatures in Denmark, 1994-2010. BMC Infect Dis. 2011; 11:350. DOI: 10.1186/1471-2334-11-350. PMID: 22176601. PMCID: PMC3264536.

13. Nunes B, Viboud C, Machado A, Ringholz C, Rebelo-de-Andrade H, Nogueira P, et al. Excess mortality associated with influenza epidemics in Portugal, 1980 to 2004. PLoS One. 2011; 6(6):e20661. DOI: 10.1371/journal.pone.0020661. PMID: 21713040. PMCID: PMC3119666.

14. Tsai TF. Fluad®-MF59®-adjuvanted influenza vaccine in older adults. Infect Chemother. 2013; 45(2):159–174. DOI: 10.3947/ic.2013.45.2.159. PMID: 24265964. PMCID: PMC3780956.

15. Giacchetta I, Primieri C, Cavalieri R, Domnich A, de Waure C. The burden of seasonal influenza in Italy: a systematic review of influenza-related complications, hospitalizations, and mortality. Influenza Other Respir Viruses. 2021; 16(2):351–365. DOI: 10.1111/irv.12925. PMID: 34704361. PMCID: PMC8818820.

16. Li S, Liu SS, Zhu AQ, Cui JZ, Qin Y, Zheng JD, et al. The mortality burden of influenza in China: a systematic review. Zhonghua Yu Fang Yi Xue Za Zhi. 2019; 53(10):1049–1055. DOI: 10.3760/cma.j.issn.0253-9624.2019.10.018.

17. Li L, Yan ZL, Luo L, Liu W, Yang Z, Shi C, et al. Influenza-associated excess mortality by age, sex, and subtype/lineage: population-based time-series study with a distributed-lag nonlinear model. JMIR Public Health Surveill. 2023; 9:e42530. DOI: 10.2196/42530. PMID: 36630176. PMCID: PMC9878364.

18. Jang H, Cho J, Cho SK, Lee D, Cho S, Koh SB, et al. All-cause and cause-specific mortality attributable to seasonal influenza: a nationwide matched cohort study. J Korean Med Sci. 2023; 38(25):e188. DOI: 10.3346/jkms.2023.38.e188. PMID: 37365724. PMCID: PMC10293660.

19. Hong K, Sohn S, Chun BC. Estimating influenza-associated mortality in Korea: the 2009-2016 seasons. J Prev Med Public Health. 2019; 52(5):308–315. DOI: 10.3961/jpmph.19.156. PMID: 31588700. PMCID: PMC6780294.

20. Ohmi K, Marui E. Estimation of the excess death associated with influenza pandemics and epidemics in Japan after world war II: relation with pandemics and the vaccination system. Nihon Koshu Eisei Zasshi. 2011; 58(10):867–878.

21. Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine. 2008; 26(Suppl 4):D17–D22. DOI: 10.1016/j.vaccine.2008.07.048. PMID: 19230153.

22. Okoli GN, Racovitan F, Abdulwahid T, Righolt CH, Mahmud SM. Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: a systematic review and meta-analysis of the evidence from test-negative design studies after the 2009/10 influenza pandemic. Vaccine. 2021; 39(8):1225–1240. DOI: 10.1016/j.vaccine.2021.01.032. PMID: 33494964.

23. Guo J, Chen X, Guo Y, Liu M, Li P, Tao Y, et al. Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: a systematic review, meta-analysis and meta-regression of test-negative design studies. Vaccine. 2024; 42(8):1883–1891. DOI: 10.1016/j.vaccine.2024.02.059. PMID: 38423813.

24. Rondy M, El Omeiri N, Thompson MG, Levêque A, Moren A, Sullivan SG. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: a systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017; 75(5):381–394. DOI: 10.1016/j.jinf.2017.09.010. PMID: 28935236. PMCID: PMC5912669.

25. Lewis NM, Zhu Y, Peltan ID, Gaglani M, McNeal T, Ghamande S, et al. Vaccine effectiveness against influenza A–associated hospitalization, organ failure, and death: United States, 2022–2023. Clin Infect Dis. 2024; 78(4):1056–1064. DOI: 10.1093/cid/ciad677. PMID: 38051664.

26. Seppälä E, Dahl J, Veneti L, Rydland KM, Klüwer B, Rohringer A, et al. COVID-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: a population-based cohort study, 3 October 2022 to 20 June 2023. Vaccine. 2024; 42(3):620–628. DOI: 10.1016/j.vaccine.2023.12.050. PMID: 38142215.

27. Yun JW, Noh JY, Song JY, Chun C, Kim Y, Cheong HJ. The Korean influenza national immunization program: history and present status. Infect Chemother. 2017; 49(4):247–254. DOI: 10.3947/ic.2017.49.4.247. PMID: 29299891. PMCID: PMC5754334.

28. Seidman JC, Richard SA, Viboud C, Miller MA. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respir Viruses. 2011; 6(1):52–62. DOI: 10.1111/j.1750-2659.2011.00268.x. PMID: 21668661. PMCID: PMC3175249.

29. Domnich A, de Waure C. Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis. Int J Infect Dis. 2022; 122:855–863. DOI: 10.1016/j.ijid.2022.07.048. PMID: 35878803.

30. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol. 2010; 10:18. DOI: 10.1186/1471-2288-10-18. PMID: 20210985. PMCID: PMC2851702.

31. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine. 2010; 28(23):3929–3935. DOI: 10.1016/j.vaccine.2010.03.067. PMID: 20394719.

32. Noh JY, Kim WJ. Influenza vaccines: unmet needs and recent developments. Infect Chemother. 2013; 45(4):375–386. DOI: 10.3947/ic.2013.45.4.375. PMID: 24475351. PMCID: PMC3902815.

33. Choi WS, Song JY, Kwon KT, Lee HJ, Choo EJ, Baek J, et al. Recommendations for adult immunization by the Korean Society of Infectious Diseases, 2023: minor revisions to the 3rd edition. Infect Chemother. 2024; 56(2):188–203. DOI: 10.3947/ic.2023.0072. PMID: 38960738. PMCID: PMC11224039.

34. Choi WS. Adult immunization policy in Korea. Infect Chemother. 2023; 55(3):317–321. DOI: 10.3947/ic.2023.0089. PMID: 37794577. PMCID: PMC10551718.

35. Ng TWY, Cowling BJ, Gao HZ, Thompson MG. Comparative immunogenicity of enhanced seasonal influenza vaccines in older adults: a systematic review and meta-analysis. J Infect Dis. 2019; 219(10):1525–1535. DOI: 10.1093/infdis/jiy720.

36. Boikos C, McGovern I, Ortiz JR, Puig-Barberà J, Versage E, Haag M. Relative vaccine effectiveness of adjuvanted trivalent influenza vaccine over three consecutive influenza seasons in the United States. Vaccines. 2022; 10(9):1456. DOI: 10.3390/vaccines10091456. PMID: 36146534. PMCID: PMC9504704.

37. Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis. Vaccine. 2021; 39(Suppl 1):A24–A35. DOI: 10.1016/j.vaccine.2020.09.004. PMID: 33422382.